A generic alternative indicated for Heart and Blood Pressure. Facilitates improved cardiac blood flow to decrease the frequency of chronic chest pain episodes.
An anti-anginal agent formulated to manage chronic chest pain and designed to alleviate angina frequency to support improved heart function.
Mechanism of Action
It inhibits the late inward sodium current in heart cells. This reduces calcium overload, which improves heart muscle relaxation and reduces oxygen demand.
Route of Administration
Oral
Onset Time
Days to weeks
Duration
12 hours
Contraindications
Liver cirrhosis, Use of strong CYP3A inhibitors, Use of strong CYP3A inducers, Allergy to ranolazine
Severe Adverse Events
QT prolongation, Kidney failure (in high-risk patients), Severe dizziness/fainting, Blood count changes
Information for Ranexa is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
